Abstract
Contemporary immunosuppression, which is almost universally cyclosporine A (CsA)-based, has produced progressive improvements in transplantation results. The combination of CsA with other agents like azathioprine, prednisone, anti-lymphocyte/anti-thymocyte globulins (ALG), and anti-CD3 antibody (OKT-3) may provide a smoother post-transplant course, but CsA toxicity remains a potentially important clinical problem. Newer agents like FK-506, RS-61443, rapamycin, deoxyspergualin, and monoclonal antibodies may improve results further with less toxicity.

This publication has 0 references indexed in Scilit: